Who is sponsoring NCT03196076?

NCT03196076 is sponsored by University of North Carolina, Chapel Hill.

What drugs are being tested in NCT03196076?

Interventions in NCT03196076: Perflutren Lipid microsphere.

What condition does NCT03196076 study?

NCT03196076 studies Chronic Kidney Diseases, Cystic Kidney Disease.

Is NCT03196076 still recruiting?

NCT03196076 is currently completed. Last updated 21 July 2021.

Are results published for NCT03196076?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-07-21 · How we verify

NCT03196076: CEUS-CKDx

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Contrast-enhanced Ultrasound for Complex Kidney Lesion Diagnosis in Patients With CKD Extension

Completed Phase 2 Results posted Last updated 21 July 2021

What this trial tests

Phase 2 trial testing Perflutren Lipid microsphere in Chronic Kidney Diseases in 25 participants. Completed in 19 March 2021.

Timeline

28 August 2017

Primary endpoint
19 March 2021

19 March 2021

Quick facts

Lead sponsor	University of North Carolina, Chapel Hill
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	25
Start date	28 August 2017
Primary completion	19 March 2021
Estimated completion	19 March 2021
Sites	1 location across United States

Drugs / interventions tested

Perflutren Lipid microsphere — full drug profile →

Conditions studied

Chronic Kidney Diseases — all drugs for Chronic Kidney Diseases →
Cystic Kidney Disease — all drugs for Cystic Kidney Disease →

Sponsor

University of North Carolina, Chapel Hill

Who can join

18 and older, any sex, with Chronic Kidney Diseases or Cystic Kidney Disease. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Participants With Change in Radiologist's Lesion Evaluation Primary · 1 year

Lesions will be assessed for change in size, calcification, and septation using Bosniak criteria to determine whether a lesion has progressed, regressed or is stable.

Group	Value	95% CI
Perflutren Lipid Microsphere (Healthy Subjects)	0
Perflutren Lipid Microsphere (Patients With Kidney Lesions)	11
Perflutren Lipid Microsphere (Healthy Subjects)	0
Perflutren Lipid Microsphere (Patients With Kidney Lesions)	1
Perflutren Lipid Microsphere (Healthy Subjects)	0
Perflutren Lipid Microsphere (Patients With Kidney Lesions)	2
Perflutren Lipid Microsphere (Healthy Subjects)	0
Perflutren Lipid Microsphere (Patients With Kidney Lesions)	1

Sponsor's own description

The purpose of this research study is to evaluate contrast-enhanced ultrasound for kidney malignancies.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Bubble-Based Drug Delivery Systems: Next-Generation Diagnosis to Therapy.
Kancheva M, Aronson L, Pattilachan T, Sautto F, et al · · 2023 · cited 16× · PMID 37504868 · DOI 10.3390/jfb14070373

Verify or expand the search:

Other recruiting trials for Chronic Kidney Diseases

Currently open trials in the same condition.

NCT06593392 — Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus · Phase 2 · recruiting
NCT07358572 — Eye-Brain-Kidney in CKD · recruiting
NCT06463483 — Automated Insulin Delivery in Adults With Advanced Kidney Disease · NA · recruiting
NCT06927024 — Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) in Chronic Kidney Disease (CKD) · NA · recruiting
NCT07115953 — Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension · NA · recruiting

Other University of North Carolina, Chapel Hill trials

Trials by the same sponsor.

NCT06841913 — Woodsmoke Exposure, Influenza Infection, and Nasal Immunity · Phase 4 · suspended
NCT07383428 — The INICIO-Guatemala Study · NA · not yet recruiting
NCT07528443 — Ultraprocessed Foods in Colombia · NA · not yet recruiting
NCT07507370 — CARED : A Novel Rapid Treatment Paradigm for Depression · NA · not yet recruiting
NCT07534254 — Piloting a Generative Artificial Intelligence Chatbot in a Mobile Weight Loss Program · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03196076 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of North Carolina, Chapel Hill
Last refreshed: 21 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03196076.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing